Why MedTech Backs Mundhe on Hospital Consumable Prices
The Indian medical device industry has strongly supported the call for trade margin rationalisation across hospital consumables. Recently, Maharashtra Food and Drug Administration Commissioner Tukaram Mundhe flagged astonishing price gaps between procurement costs and printed Maximum Retail Prices. In fact, state market surveys uncovered markups as high as 2,841% on common inpatient items. Consequently, key industry bodies are urging central authorities to introduce transparent, structured pricing reforms.
Unmasking the Massive Hospital Consumable Markups
During recent hospital audits, the Maharashtra FDA revealed how deeply inflated consumable pricing has become. For example, investigators found an intravenous infusion set procured at ₹11.05 carrying an MRP of ₹325. Similarly, a disposable syringe purchased for ₹6.75 reached patients with a printed tag of ₹57.20. Furthermore, hospitals billed catheters bought for ₹29.41 at ₹310. Because these inpatient supplies are non-elective necessities, admitted patients cannot negotiate costs or choose alternative products.
Why Industry Leaders Demand Trade Margin Rationalisation
Both domestic manufacturers and multinational suppliers have rallied behind Mundhe's recommendations. For instance, AiMeD emphasized that the current Drugs (Prices Control) Order of 2013 fails to regulate medical devices properly. In addition, AiMeD pointed out that artificial markups penalize ethical manufacturers who refuse to inflate prices. Therefore, the association demanded evidence-based pilot studies and immediate price rationalisation to create a fair, competitive ecosystem.
Likewise, the Medical Technology Association of India fully endorsed the proposed policy overhaul. Specifically, MTaI Chairman Pavan Choudary noted that his association has advocated for margin caps since 2016. According to industry leaders, this policy maintains essential incentives for technological innovation while eliminating exploitative intermediary profit. Moreover, structured margin caps protect healthcare workers and foster patient trust in clinical settings.
Key Regulatory Steps Recommended to the NPPA
To rectify systemic distortions, Mundhe submitted three core recommendations to the Department of Pharmaceuticals and the National Pharmaceutical Pricing Authority. First, regulators must establish clear guidelines defining acceptable margins between wholesale procurement costs and declared consumer MRPs. Second, central authorities should conduct an inter-agency review to examine hospital procurement patterns across states. Finally, structured price monitoring must encompass common bedside consumables rather than merely focusing on scheduled pharmaceutical formulations.
Clinical and Ethical Implications for Healthcare Providers
This regulatory momentum carries critical significance for treating physicians and hospital administrators. Unchecked markups on routine consumables often distort hospital billing and spark severe patient grievances. Consequently, public outrage over consumable charges damages the doctor-patient relationship and clouds clinical outcomes. By introducing transparent procurement caps, regulatory authorities can restore financial clarity to inpatient admissions. Ultimately, fair consumable pricing ensures clinical decisions remain centered on patient welfare rather than procurement margins, an essential perspective taught in programs such as a Certification Course In General Practice.
Frequently Asked Questions
Q1: What is trade margin rationalisation in healthcare?
Trade margin rationalisation establishes an upper limit on the profit margin that distributors and hospitals can add between the trade procurement price and the final maximum retail price charged to patients.
Q2: Why are hospital consumables showing markups above 2,000%?
Currently, many general medical consumables fall outside direct price caps under the Drugs (Prices Control) Order of 2013. Consequently, manufacturers and distributors set inflated MRPs, allowing intermediaries to retain massive margins during inpatient care.
Q3: How will trade margin caps affect Indian medical device manufacturers?
Transparent caps protect ethical domestic manufacturers from unfair competition against inflated trade schemes. Furthermore, this policy ensures predictable pricing while safeguarding essential commercial margins needed for research, innovation, and clinical training.
References
- MedTech sector backs Mundhe's push for trade margin rationalisation - ETHealthworld
- Maharashtra FDA Commissioner made recommendation to NPPA on pricing gap of hospital consumables - The Hindu
- Hospital consumables MRP gap: Maharashtra FDA finds mark-ups up to 2,800% - India Today
